ArticlePloS one2025
Synergistic effects of sesame oil, extra virgin olive oil, psyllium extract, and dandelion extract on cholesterol gallstone dissolution: An in vitro comparative study against Rowachol®.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCholesterol gallstones represent a significant global health burden. Current treatments, including surgery and oral dissolution agents, are often invasive or limited by side effects and variable efficacy. This study investigated the in vitro gallstone-dissolving efficacy of a natural combination-sesame oil (SO), extra virgin olive oil (EVOO), psyllium extract (PE), and dandelion extract (DE)-compared to the pharmaceutical agent Rowachol®.
methodsIn a randomized in vitro study, seventy cholesterol-dominant human gallstones were assigned to seven groups receiving either individual agents, multi-component combinations, or Rowachol® (control). Two prespecified endpoints were assessed under standardized simulated bile conditions at 48 h (T1), 96 h (T2), and 144 h (T3): dissolution rate (DR, %; weight loss) and cumulative cholesterol release (mg). Statistical analyses compared groups across time and explored potential multi-component interactions.
resultsThe four-component regimen (G6: PE + DE+SO+EVOO) showed the greatest efficacy at T3, achieving DR = 92.57% ± 4.2 and cholesterol release = 114.48 ± 4.2 mg, significantly exceeding Rowachol® (39.71% ± 1.9; 42.57 ± 1.9 mg; p < 0.001) and all other groups. Effects were time-dependent, with progressive separation from T1 to T3. Key bioactive compounds-oleic acid, taraxacin, arabinoxylan, and linoleic acid-showed strong positive correlations with dissolution outcomes (r = +0.76 to +0.94). A regression model identified these compounds as primary efficacy predictors, accounting for 94% of the observed variance (adjusted R² = 0.94).
conclusionsUnder short-term, controlled in vitro conditions, the SO+EVOO+PE + DE combination achieved a ~ 2.3-fold higher dissolution rate than Rowachol® at 144 h. These findings constitute mechanistic, hypothesis-generating evidence that clarifies how dissolution may be enhanced ex vivo. Confirmation in well-designed in-vivo models-followed by clinical studies to evaluate safety, dosing, and effectiveness-is required before any patient-care application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.